|
1
|
Malhi H and Gores GJ: Cholangiocarcinoma:
modern advances in understanding a deadly old disease. J Hepatol.
45:856–867. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Khan SA, Thomas HC, Davidson BR and
Taylor-Robinson SD: Cholangiocarcinoma. Lancet. 366:1303–1314.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Anderson C and Kim R: Adjuvant therapy for
resected extrahepatic cholangiocarcinoma: a review of the
literature and future directions. Cancer Treat Rev. 35:322–327.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhang H, Berezov A, Wang Q, et al: ErbB
receptors: from oncogenes to targeted cancer therapies. J Clin
Invest. 117:2051–2058. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zaczek A, Brandt B and Bielawski KP: The
diverse signaling network of EGFR, HER2, HER3 and HER4 tyrosine
kinase receptors and the consequences for therapeutic approaches.
Histol Histopathol. 20:1005–1015. 2005.PubMed/NCBI
|
|
6
|
Verma S, Miles D, Gianni L, et al:
Trastuzumab emtansine for HER2-positive advanced breast cancer. N
Engl J Med. 367:1783–1791. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Franklin WA, Veve R, Hirsch FR, Helfrich
BA and Bunn PA Jr: Epidermal growth factor receptor family in lung
cancer and premalignancy. Semin Oncol. 29:3–14. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Suo Z, Risberg B, Kalsson MG, et al: EGFR
family expression in breast carcinomas. c-erbB-2 and c-erbB-4
receptors have different effects on survival. J Pathol. 196:17–25.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wei Q, Shui Y, Zheng S, et al: EGFR, HER2
and HER3 expression in primary colorectal carcinomas and
corresponding metastases: Implications for targeted radionuclide
therapy. Oncol Rep. 25:3–11. 2011.PubMed/NCBI
|
|
10
|
Awaya H, Takeshima Y, Furonaka O, Kohno N
and Inai K: Gene amplification and protein expression of EGFR and
HER2 by chromogenic in situ hybridisation and immunohistochemistry
in atypical adenomatous hyperplasia and adenocarcinoma of the lung.
J Clin Pathol. 58:1076–1080. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Harder J, Waiz O, Otto F, et al: EGFR and
HER2 expression in advanced biliary tract cancer. World J
Gastroenterol. 15:4511–4517. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jaiswal BS, Kljavin NM, Stawiski EW, et
al: Oncogenic ERBB3 mutations in human cancers. Cancer Cell.
23:603–617. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fujiwara S, Ibusuki M, Yamamoto S,
Yamamoto Y and Iwase H: Association of ErbB1–4 expression in
invasive breast cancer with clinicopathological characteristics and
prognosis. Breast Cancer. Oct 26–2012.(Epub ahead of print).
|
|
14
|
Memon AA, Sorensen BS, Melgard P, Fokdal
L, Thykjaer T and Nexo E: Expression of HER3, HER4 and their ligand
heregulin-4 is associated with better survival in bladder cancer
patients. Br J Cancer. 91:2034–2041. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yoshikawa D, Ojima H, Iwasaki M, et al:
Clinicopathological and prognostic significance of EGFR, VEGF, and
HER2 expression in cholangiocarcinoma. Br J Cancer. 98:418–425.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kim HJ, Yoo TW, Park DI, et al: Gene
amplification and protein overexpression of HER-2/neu in human
extrahepatic cholangiocarcinoma as detected by chromogenic in situ
hybridization and immunohistochemistry: its prognostic implication
in node-positive patients. Ann Oncol. 18:892–897. 2007. View Article : Google Scholar
|
|
17
|
Shafizadeh N, Grenert JP, Sahai V and
Kakar S: Epidermal growth factor receptor and HER-2/neu status by
immunohistochemistry and fluorescence in situ hybridization in
adenocarcinomas of the biliary tree and gallbladder. Hum Pathol.
41:485–492. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lubner SJ, Mahoney MR, Kolesar JL, et al:
Report of a multicenter phase II trial testing a combination of
biweekly bevacizumab and daily erlotinib in patients with
unresectable biliary cancer: a phase II Consortium study. J Clin
Oncol. 28:3491–3497. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lee HJ, Chung JY, Hewitt SM, Yu E and Hong
SM: HER3 overexpression is a prognostic indicator of extrahepatic
cholangiocarcinoma. Virchows Arch. 461:521–530. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jarnagin WR, Klimstra DS, Hezel M, et al:
Differential cell cycle-regulatory protein expression in biliary
tract adenocarcinoma: correlation with anatomic site, pathologic
variables, and clinical outcome. J Clin Oncol. 24:1152–1160. 2006.
View Article : Google Scholar
|
|
21
|
Edge SB and Compton CC: The American Joint
Committee on Cancer: the 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang L, Zhang J, Yang X, et al: SOX4 is
associated with poor prognosis in prostate cancer and promotes
epithelial-mesenchymal transition in vitro. Prostate Cancer
Prostatic Dis. 16:301–307. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rajkumar T, Stamp GW, Pandha HS, Waxman J
and Gullick WJ: Expression of the type 1 tyrosine kinase growth
factor receptors EGF receptor, c-erbB2 and c-erbB3 in bladder
cancer. J Pathol. 179:381–385. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ito Y, Takeda T, Sasaki Y, et al:
Expression and clinical significance of the erbB family in
intrahepatic cholangiocellular carcinoma. Pathol Res Pract.
197:95–100. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Nakazawa K, Dobashi Y, Suzuki S, Fujii H,
Takeda Y and Ooi A: Amplification and overexpression of c-erbB-2,
epidermal growth factor receptor, and c-met in biliary tract
cancers. J Pathol. 206:356–365. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Endreffy E, Burg K, Gyurkovits K, Kalman
M, Laszlo A and Rasko I: Allele frequencies of cystic
fibrosis-linked markers and F508 deletion in affected Hungarian
families. Acta Paediatr Hung. 32:101–113. 1992.PubMed/NCBI
|
|
27
|
Ruys AT, Groot Koerkamp B, Wiggers JK,
Klumpen HJ, Ten Kate FJ and van Gulik TM: Prognostic biomarkers in
patients with resected cholangiocarcinoma: a systematic review and
meta-analysis. Ann Surg Oncol. 21:487–500. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lee J, Park SH, Chang HM, et al:
Gemcitabine and oxaliplatin with or without erlotinib in advanced
biliary-tract cancer: a multicentre, open-label, randomised, phase
3 study. Lancet Oncol. 13:181–188. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chiorean EG, Ramasubbaiah R, Yu M, et al:
Phase II trial of erlotinib and docetaxel in advanced and
refractory hepatocellular and biliary cancers: Hoosier Oncology
Group GI06–101. Oncologist. 17:132012.PubMed/NCBI
|
|
30
|
Barnes NL, Khavari S, Boland GP, Cramer A,
Knox WF and Bundred NJ: Absence of HER4 expression predicts
recurrence of ductal carcinoma in situ of the breast. Clin Cancer
Res. 11:2163–2168. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Edwards J, Traynor P, Munro AF, Pirret CF,
Dunne B and Bartlett JM: The role of HER1-HER4 and EGFRvIII in
hormone-refractory prostate cancer. Clin Cancer Res. 12:123–130.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Thybusch-Bernhardt A, Beckmann S and Juhl
H: Comparative analysis of the EGF-receptor family in pancreatic
cancer: expression of HER-4 correlates with a favourable tumor
stage. Int J Surg Investig. 2:393–400. 2001.
|
|
33
|
Bussu F, Ranelletti FO, Gessi M, et al:
Immunohistochemical expression patterns of the HER4 receptors in
normal mucosa and in laryngeal squamous cell carcinomas:
antioncogenic significance of the HER4 protein in laryngeal
squamous cell carcinoma. Laryngoscope. 122:1724–1733. 2012.
View Article : Google Scholar
|
|
34
|
Gilbertson RJ, Perry RH, Kelly PJ, Pearson
AD and Lunec J: Prognostic significance of HER2 and HER4
coexpression in childhood medulloblastoma. Cancer Res.
57:3272–3280. 1997.PubMed/NCBI
|
|
35
|
Rickert CH: Prognosis-related molecular
markers in pediatric central nervous system tumors. J Neuropathol
Exp Neurol. 63:1211–1224. 2004.PubMed/NCBI
|
|
36
|
Settakorn J, Kaewpila N, Burns GF and
Leong AS: FAT, E-cadherin, β catenin, HER 2/neu, Ki67
immuno-expression, and histological grade in intrahepatic
cholangiocarcinoma. J Clin Pathol. 58:1249–1254. 2005.
|
|
37
|
Buchler P, Reber HA, Buchler MC, et al:
Therapy for pancreatic cancer with a recombinant humanized
anti-HER2 antibody (herceptin). J Gastrointest Surg. 5:139–146.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Reschke M, Mihic-Probst D, van der Horst
EH, et al: HER3 is a determinant for poor prognosis in melanoma.
Clin Cancer Res. 14:5188–5197. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yi ES, Harclerode D, Gondo M, et al: High
c-erbB-3 protein expression is associated with shorter survival in
advanced non-small cell lung carcinomas. Mod Pathol. 10:142–148.
1997.PubMed/NCBI
|
|
40
|
Begnami MD, Fukuda E, Fregnani JH, et al:
Prognostic implications of altered human epidermal growth factor
receptors (HERs) in gastric carcinomas: HER2 and HER3 are
predictors of poor outcome. J Clin Oncol. 29:3030–3036. 2011.
View Article : Google Scholar : PubMed/NCBI
|
